|Articles|November 2, 2002

Pharmaceutical Technology-11-02-2002
Volume 26
Issue 11

Major Changes Ahead for FDA

FDA is juggling momentous changes, including new leadership and the proposed transfer of oversight for therapeutic biotech drugs.

External Link - article-40954.pdf

Articles in this issue

over 23 years ago

Article

Contract Services

over 23 years ago

Article

Estimation of Distribution Coefficients from the Partition Coefficient and pKa

over 23 years ago

Article

Residual Solvent Analysis in Pharmaceuticals

over 23 years ago

Article

Preparation and In Vitro Evaluation of Miconazole Nitrate-Loaded Topical Liposomes

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Scientist working in biosimilars development with futuristic medical technology and digital interface elements | Image Credit: ©KHAN VECTOR CO. -stock.adobe.com

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

ByKimberly Salgado

June 3rd 2026

Ebola virus outbreak biosecurity interface in medical laboratory, infectious disease prevention healthcare emergency, quarantine containment diagnostics vaccine research, public health | Image Credit: ©Sapra -stock.adobe.com

EMA Collaborates with African Regulators on Ebola Treatments

BySusan Haigney

June 3rd 2026

Adeno-associated virus. AAV virus genome. Adenoviral pneumonia, arthritis, bronchitis, hepatitis, cystitis. Adenovirus as vectors for gene therapy. Genetic material transmission to cell. Biotech 3D | Image Source: ©Corona Borealis -stock.adobe.com

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

ByJohn Muganga

June 3rd 2026

Single use syringe for injection treatment on medical table with vials of liquid drug doses flu shots at background. Vaccination or immunization care concept | Image Credit: ©Mikhailov Studio -stock.adobe.com

USP Publishes Biologics Standards for Public Comment

BySusan Haigney

June 2nd 2026

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | © JHVEPhoto - stock.adobe.com (330225712)

CPHI Americas: How FDA Instability Is Reshaping Pharmaceutical Development

ByZachary Zubulake

June 2nd 2026

Major Changes Ahead for FDA

Articles in this issue

Related Content

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

EMA Collaborates with African Regulators on Ebola Treatments

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

USP Publishes Biologics Standards for Public Comment

CPHI Americas: How FDA Instability Is Reshaping Pharmaceutical Development

Trending on Pharmaceutical Technology

FDA Guidance for Accelerating Gene Therapies for Rare Diseases

Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance

Implications of Pediatric Inhaled Insulin Approval

Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs

Generic GLP-1s Enter Canadian Market